# Point Of Care Glucose Testing Market

> Point Of Care Glucose Testing Market Research Report: Size, Share, Trend Analysis By Product Type (Lancing Devices and Strips and Blood-Glucose Meter), By Applications (Type-1 Diabetes and Type-2 Diabetes), By End Users (Hospitals and Clinics, Home Care Settings, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.1%
- **2024:** $ 3.53 Billion
- **2025:** $ 3.71 Billion
- **2035:** $ 6.1 Billion
- **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Bayer AG (DE), Johnson & Johnson (US), Siemens Healthineers (DE), Dexcom Inc. (US), Ascensia Diabetes Care (DE), Terumo Corporation (JP), Nova Biomedical (US)

**Report ID:** MRFR/HC/10743-HCR · **Pages:** 132 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/point-of-care-glucose-testing-market-12264

---

## Market Summary

## **Global Point Of Care Glucose Testing Market Overview**

As per MRFR analysis, the Point Of Care Glucose Testing Market Size was estimated at 3.53 (USD Billion) in 2024. The Point Of Care Glucose Testing Market Industry is expected to grow from 3.71 (USD Billion) in 2025 to 5.81 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.10% during the forecast period (2025 - 2034).
The ageing population, point-of-care (POC) diagnostic technologies' capacity to provide quick findings, and better patient care are the key market drivers enhancing the market growth.

## **Point Of Care Glucose Testing Market Trends**

The rising number of diabetics is driving market CAGR for point of care glucose testing. One of the top concerns for healthcare providers to reduce mortality is diabetes management. The Diabetes Research Foundation found that among COVID-19 patients, diabetes doubles the probability of a catastrophic result. PoC glucose testing systems are projected to rise due to rising diabetes awareness, limited healthcare access, a shortage of medical experts, and the greatest global prevalence documented in Asian nations. This presents an opportunity to lessen the financial burden of healthcare while enhancing patient outcomes.

The implementation of supportive regulatory measures to encourage PoC glucose tests is anticipated to influence the industry significantly. For instance, introducing the Clinical Laboratory Improvement Amendments (CLIA) in the United States will increase utilization rates throughout the projected period. Healthcare providers using non-traditional laboratory locations, such as ERs, doctor's offices, pharmacy clinics, health department clinics, and other healthcare institutions, can use CLIA-waived tests. Diabetes is becoming more common worldwide, growing the market's patient base.

Additionally, it is anticipated that the availability of unmet medical needs for diagnosing and managing diabetes and the rise in patient awareness would enhance the need for POC diagnostics. The International Diabetes Federation estimates that 537 million people worldwide will have diabetes by 2021, rising to 643 million by 2030 and 783 million by 2045.

The need for short turn-around testing (STAT) has grown due to the healthcare sector's emphasis on shorter hospital stays, improved acute care, and outlying surgical centers. POC management tools allow patients and healthcare professionals to simply collect, distribute, and maintain specimens to satisfy regulatory obligations. Patient treatment results are improved, and turnaround time is reduced by point-of-care glucose testing. Most PoC testing techniques do not lyse the RBCs and just require a drop or finger stick of blood.

This minimally invasive blood glucose monitoring method eliminates the requirement for a continuous intravenous catheter with a glucose drip attached to its tip and enables real-time bedside glucose monitoring. The emergence of handheld, lightweight, portable devices with increased and extended communication capabilities results from technological advancements. In hospitals and clinical settings worldwide, point-of-care glucose monitoring equipment has emerged as the standard for near-patient glucose monitoring. Point-of-care blood glucose meters utilize whole blood instead of measuring blood glucose using plasma at the bedside. Thus, driving the Point Of Care Glucose Testing market revenue.

## **Point Of Care Glucose Testing Market Segment Insights**

### **Point Of Care Glucose Testing Product Type Insights**

Based on product type, the Point Of Care Glucose Testing Market segmentation includes lancing devices and strips, and blood-glucose meters. The lancing devices and strips segment dominated the market, accounting for 35% of market revenue. More people rely on lancing devices to monitor their blood glucose levels due to the rising prevalence of diabetes. People with diabetes use lancing devices to collect blood samples to evaluate their blood glucose levels.

### **Point Of Care Glucose Testing Application Insights**

Based on application, the Point Of Care Glucose Testing Market segmentation includes type-1 diabetes and type-2 diabetes. The type-2 diabetes segment dominated the market. Many people are affected by type 2 diabetes. It's one of the key causes of the rising demand for insulin medications. Due to the wide range of products and innovative ideas, the insulin market has fantastic prospects for growth and development. As a result, the anticipated expansion of the worldwide [type 2 diabetes](../../../reports/type-2-diabetes-mellitus-treatment-market-5669) market will be driven by an increase in insulin demand.

### **Point Of Care Glucose Testing End User Insights**

Based on End User, the Point Of Care Glucose Testing Market segmentation includes hospitals and clinics, home care settings, and others. The home care settings generated the most income. Due to the widespread use of point-of-care glucose testing equipment in home care settings, the high number of diabetes patients who check their blood sugar levels to monitor the impact of meals at home, the rise in the number of older adults who need medical care at home, and increased public awareness of the use of point-of-care glucose testing equipment at home.

**Figure 1: Point Of Care Glucose Testing Market, by End User, 2022 & 2032 (USD Billion)**

**_Source: Secondary Research, Primary Research, MRFR Database and Analyst Review_**

### **Point Of Care Glucose Testing Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Point Of Care Glucose Testing market area will dominate this market; rising rates of lifestyle disorders, an increase in product approvals, and an increase in government-led campaigns to promote the use of point-of-care glucose monitoring devices. Modern healthcare infrastructure, a growing desire for in-home care settings, and a strong presence of major market participants are important aspects anticipated to propel market revenue growth.

Further, the major countries studied in the market report are The US, Canada, China, Japan, German, France, the UK, Italy, Spain, India, Australia, South Korea, and Brazil.

**Figure 2: POINT OF CARE GLUCOSE TESTING MARKET SHARE BY REGION 2022 (USD Billion)**

**_Source: Secondary Research, Primary Research, MRFR Database and Analyst Review_**

Europe has the second-largest market share for Point Of Care Glucose Testing. Growing consumer awareness of glucose monitoring devices. Furthermore, the German Point Of Care Glucose Testing market dominated, while the UK Point Of Care Glucose Testing market grew fastest in Europe.

From 2023 to 2032, the Asia-Pacific Point Of Care Glucose Testing Market will develop the quickest CAGR Applications of Point Of Care Glucose Testing. Due to the quick expansion of medical facilities, the favorable reimbursement environment, the expanding use of point-of-care glucose testing for personal and professional purposes, the rising incidence of diabetes in APAC nations, and the rising investment in the R&D industry. Furthermore, China's Point Of Care Glucose Testing market had the highest market share. In contrast, the Asia-Pacific region's Point Of Care Glucose Testing market in India was the one that was growing the quickest.

**Point Of Care Glucose Testing Key Market Players & Competitive Insights**

Leading market companies are extensively spending R&D on increasing their product lines, which will help the Point Of Care Glucose Testing market grow even more. Important market developments include contractual agreements, new product releases, acquisitions and mergers, greater investments, and collaboration with other organizations. The Point Of Care Glucose Testing must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.

Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Point Of Care Glucose Testing to serve clients and expand the market sector. The Point Of Care Glucose Testing has provided some of the most important benefits recently. Vital and other major competitors in the Point Of Care Glucose Testing market are seeking to improve market demand by investing in R&D efforts.

Vital is altering the way we view health. Healthcare that is accessible, proactive, and preventative is made possible through Vital. They're beginning with a lab testing strategy that is completely disruptive. They are a group of partners who are re-engineering how healthcare is delivered, backed by many years of R&D by top-tier scientists and engineers. Vital is altering the way we view health. Their goals include preventing disease, reducing wellbeing disparities, giving people back control, and empowering healthcare professionals to produce better results.

In July 2023, To enable clinicians to perform tests, make diagnoses, and treat patients in a single visit, Vital Biosciences introduced VitalOne. This ground-breaking point-of-care lab testing platform offers blood testing anywhere.

Haemoglobin, glycated hemoglobin (HbA1c), glucose, and lactate point-of-care (POCT) devices and assays are produced by the international medical producer EKF Diagnostics. Its POC analyzers are made to be used in medical offices, clinics, hospitals, and laboratories to deliver prompt, precise findings at a reasonable cost. For usage in hospital laboratories, the EKF Central Laboratory division produces a wide range of reagents for various automated and semi-automated analyzers. To create customized kits, EKF Contract Manufacturing offers specialized services to the healthcare and diagnostics sectors.

EKF can offer bulk formulation, dispensing, and kitting services as well as advice and assistance on regulatory needs, thanks to US, UK, and Germany facilities. The packaging, IFUs, labeling sourcing, printing, and compilation services provided by EKF are also included. In March 2021, The STAT-Site WB -ketone and glucose portable analyzer, just released by EKF Diagnostics (Cardiff, Wales, UK), was on display at this year's MEDICA, the largest medical trade expo for medical technology, electromedical equipment, laboratory equipment, diagnostics, and pharmaceuticals.

**Key Companies in the Point Of Care Glucose Testing market include**

### Point Of Care Glucose Testing Market Industry Developments

- **Q2 2024: Abbott launches next-generation FreeStyle Libre 4 continuous glucose monitor in Europe** Abbott announced the commercial launch of its FreeStyle Libre 4, a next-generation continuous glucose monitoring system, in select European markets. The device features enhanced accuracy and new connectivity features for point-of-care and home use.
- **Q2 2024: Dexcom Receives FDA Clearance for G7 Continuous Glucose Monitoring System for Hospital Point-of-Care Use** Dexcom announced that the U.S. FDA has cleared its G7 continuous glucose monitoring system for use in hospital point-of-care settings, expanding its application beyond personal diabetes management.
- **Q1 2024: Roche launches Accu-Chek Instant Connect, a Bluetooth-enabled point-of-care glucose meter** Roche introduced the Accu-Chek Instant Connect, a new Bluetooth-enabled glucose meter designed for rapid point-of-care testing and seamless integration with electronic health records in clinical settings.
- **Q2 2024: Ascensia Diabetes Care and Glooko Announce Partnership to Integrate Point-of-Care Glucose Data with Digital Diabetes Management Platform** Ascensia Diabetes Care entered a partnership with Glooko to integrate data from its point-of-care glucose meters into Glooko’s digital diabetes management platform, enabling real-time data sharing between patients and healthcare providers.
- **Q3 2024: Trividia Health Receives CE Mark for TRUE METRIX AIR Professional Point-of-Care Glucose Meter** Trividia Health announced it has received CE Mark approval for its TRUE METRIX AIR Professional, a new point-of-care glucose meter intended for use in hospitals and clinics across Europe.
- **Q1 2024: PTS Diagnostics Launches New Point-of-Care Glucose and HbA1c Analyzer in the U.S.** PTS Diagnostics launched a new combined glucose and HbA1c analyzer for point-of-care use in the United States, targeting primary care clinics and community health centers.
- **Q2 2024: BioIntelliSense raises $45M Series B to expand wearable point-of-care glucose monitoring platform** BioIntelliSense secured $45 million in Series B funding to accelerate the development and commercialization of its wearable point-of-care glucose monitoring platform for both hospital and home settings.
- **Q2 2024: Siemens Healthineers acquires GlySure, expanding point-of-care glucose monitoring portfolio** Siemens Healthineers completed the acquisition of GlySure, a company specializing in continuous intravascular glucose monitoring, to strengthen its point-of-care diagnostics offerings.
- **Q3 2024: Nova Biomedical Opens New Manufacturing Facility for StatStrip Glucose Hospital Meters** Nova Biomedical opened a new manufacturing facility dedicated to producing its StatStrip point-of-care glucose meters for hospital use, aiming to meet growing demand in North America and Europe.
- **Q2 2025: AgaMatrix Receives FDA 510(k) Clearance for WaveSense Jazz Wireless Pro Point-of-Care Glucose Meter** AgaMatrix announced it has received FDA 510(k) clearance for its WaveSense Jazz Wireless Pro, a new point-of-care glucose meter designed for professional healthcare settings.
- **Q1 2025: EKF Diagnostics Launches STAT-Site WB Pro, a New Point-of-Care Glucose and Ketone Analyzer** EKF Diagnostics launched the STAT-Site WB Pro, a new analyzer capable of measuring both glucose and ketone levels at the point of care, targeting emergency and critical care environments.
- **Q2 2025: Medtronic Announces Partnership with Microsoft to Develop AI-Driven Point-of-Care Glucose Monitoring Solutions** Medtronic entered a partnership with Microsoft to co-develop artificial intelligence-powered solutions for point-of-care glucose monitoring, aiming to enhance clinical decision support and patient outcomes.

## **Point Of Care Glucose Testing Market Segmentation**

### **Point Of Care Glucose Testing Type Outlook**

### **Point of care glucose testing Application Outlook (USD Billion, 2018-2032)**

### **Point of care glucose testing End User Outlook (USD Billion, 2018-2032)**

### **Point Of Care Glucose Testing Regional Outlook**

## Market Drivers

### Rising Prevalence of Diabetes

The increasing prevalence of diabetes worldwide is a primary driver for the Point Of Care Glucose Testing Market. According to recent estimates, the number of individuals diagnosed with diabetes is projected to reach approximately 700 million by 2045. This alarming trend necessitates efficient and accessible glucose monitoring solutions, thereby propelling the demand for point of care testing devices. As healthcare systems strive to manage this chronic condition effectively, the Point Of Care Glucose Testing Market is likely to experience substantial growth. The convenience and immediacy of these testing methods align with the needs of both patients and healthcare providers, fostering a shift towards more decentralized healthcare solutions.

### Shift Towards Home Healthcare

The ongoing shift towards home healthcare is reshaping the Point Of Care Glucose Testing Market. Patients increasingly prefer to manage their health conditions from the comfort of their homes, leading to a rise in demand for at-home testing devices. This trend is supported by the growing awareness of diabetes management and the need for regular monitoring. The convenience of home testing not only empowers patients but also reduces the burden on healthcare facilities. As a result, the Point Of Care Glucose Testing Market is likely to see a significant uptick in sales of home-use glucose testing devices, reflecting a broader movement towards personalized healthcare solutions.

### Supportive Regulatory Environment

A supportive regulatory environment is fostering innovation and growth within the Point Of Care Glucose Testing Market. Regulatory bodies are increasingly streamlining approval processes for new testing devices, encouraging manufacturers to bring innovative solutions to market. This regulatory support not only enhances the availability of advanced glucose testing technologies but also instills confidence among healthcare providers and patients. As regulations evolve to accommodate new technologies, the Point Of Care Glucose Testing Market is likely to benefit from increased product offerings and improved accessibility, ultimately enhancing patient care and management of diabetes.

### Increased Focus on Preventive Healthcare

The heightened emphasis on preventive healthcare is driving growth in the Point Of Care Glucose Testing Market. Healthcare providers are increasingly recognizing the importance of early detection and management of diabetes to prevent complications. This shift is leading to greater investments in point of care testing solutions that facilitate timely interventions. As healthcare systems prioritize preventive measures, the demand for glucose testing devices that can be used in various settings, including clinics and pharmacies, is expected to rise. Consequently, the Point Of Care Glucose Testing Market is poised for expansion as stakeholders seek to enhance patient outcomes through proactive health management.

### Technological Innovations in Testing Devices

Technological advancements in glucose testing devices are significantly influencing the Point Of Care Glucose Testing Market. Innovations such as continuous glucose monitoring systems and smartphone-integrated devices enhance user experience and accuracy. These advancements not only improve patient compliance but also facilitate real-time data sharing with healthcare professionals. The market is witnessing a surge in demand for devices that offer rapid results and user-friendly interfaces. As technology continues to evolve, the Point Of Care Glucose Testing Market is expected to expand, driven by the introduction of more sophisticated and efficient testing solutions that cater to the diverse needs of patients.

## Future Outlook

The Point Of Care Glucose Testing Market is projected to grow at a 5.1% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and demand for rapid testing solutions.

**New opportunities:**

- Development of portable glucose monitoring devices for home use. Integration of AI analytics for personalized diabetes management. Expansion of telehealth services for remote glucose monitoring.

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

## Segment Insights

### By Type: Lancing Devices and Strips (Largest) vs. Blood-Glucose Meter (Fastest-Growing)

In the Point Of Care Glucose Testing Market, Lancing Devices and Strips hold a significant share, contributing to the overall point of care glucose testing market share due to steady demand for consumables. This segment benefits from the steady demand for consumables that work in tandem with glucose meters, providing a reliable means of blood sampling and testing. On the other hand, Blood-Glucose Meters are experiencing rapid growth, fueled by technological advancements and the increasing prevalence of diabetes worldwide. These devices have become more user-friendly and connected, leading to an uptick in adoption rates among patients and healthcare providers alike.

Lancing Devices and Strips (Dominant) vs. Blood-Glucose Meter (Emerging)

Lancing Devices and Strips serve as the backbone of the Point Of Care Glucose Testing Market, showcasing dominance through their essential role in the glucose testing process. These devices are characterized by their reliability and ease of use, providing users with the necessary tools to obtain blood samples for glucose monitoring. Conversely, Blood-Glucose Meters are emerging as a powerhouse segment due to the integration of smart technologies, such as mobile app connectivity and advanced data analytics. These innovations enhance patient engagement and provide healthcare professionals with valuable insights into glucose trends, thereby supporting better patient outcomes. This dynamic is crucial, as the market adapts to the growing demand for efficient and patient-centered diabetes management solutions.

### By Application: Type-2 Diabetes (Largest) vs. Type-1 Diabetes (Fastest-Growing)

In the Point Of Care Glucose Testing Market, the distribution of application shares indicates that Type-2 Diabetes holds the largest market share, significantly leading over [Type-1 Diabetes](https://www.marketresearchfuture.com/reports/type-1-diabetes-treatment-market-8199). This dominance is attributed to the higher prevalence of Type-2 Diabetes globally, combined with increasing awareness and screening practices. Healthcare providers are focusing more on Type-2 due to its association with lifestyle factors, which necessitates regular monitoring for effective management and prevention strategies. Conversely, the Type-1 Diabetes segment is experiencing rapid growth, driven by advancements in testing technologies and increased investments in diabetes management. The rise in pediatric and adolescent diagnoses, along with a growing push for personalized healthcare, is further propelling this segment. Initiatives aimed at improving awareness and education around Type-1 Diabetes are also contributing to its accelerated market growth.

Application: Type-2 Diabetes (Dominant) vs. Type-1 Diabetes (Emerging)

The Type-2 Diabetes application in the Point Of Care Glucose Testing Market remains dominant, attracting significant usage due to its vast patient population. Patients often require frequent monitoring, creating consistent demand for testing products. The convenience and accessibility of point-of-care testing align well with the management needs of Type-2 Diabetes patients. On the other hand, the Type-1 Diabetes application, though currently smaller, is emerging rapidly. This segment is characterized by rising incidences among younger populations, requiring tailored testing solutions. The advancements in technology and a growing focus on continuous glucose monitoring systems are positioning Type-1 Diabetes as a crucial part of market growth, with innovative solutions catering to the unique needs of these patients.

### By End User: Hospitals and Clinics (Largest) vs. Home Care Settings (Fastest-Growing)

In the Point Of Care Glucose Testing Market, the end-user segment is primarily dominated by Hospitals and Clinics, which account for a significant portion of market share. This preference can be attributed to the high volume of routine glucose monitoring required in clinical settings where patient management is critical. On the other hand, Home Care Settings are gaining traction, reflecting a shift towards patient-centric care and the growing demand for at-home monitoring solutions, especially with the rise of chronic diseases such as diabetes.

End User: Hospitals and Clinics (Dominant) vs. Home Care Settings (Emerging)

Within the Point Of Care Glucose Testing Market, Hospitals and Clinics emerge as the dominant end-users due to their extensive infrastructure and need for accurate and immediate glucose readings to make timely clinical decisions. These facilities typically have sophisticated testing modalities and skilled personnel optimizing their testing processes. On the contrary, Home Care Settings are classified as an emerging segment, driven by the increasing trend of self-monitoring among patients, coupled with advancements in accessible technology. As diabetes management continues to shift towards decentralized care, home testing devices are becoming essential for empowering patients, ultimately leading to improved outcomes.

## Regional Market Share Analysis

### North America : Healthcare Innovation Leader

North America is the largest market for Point Of Care Glucose Testing Market, holding approximately 45% of the global share. The region's growth is driven by increasing diabetes prevalence, technological advancements, and supportive healthcare policies. Regulatory bodies like the FDA have streamlined approval processes for new devices, enhancing market dynamics. The demand for rapid testing solutions in both clinical and home settings is also on the rise, further propelling market growth. The United States leads the North American market, followed by Canada. Major players such as Abbott Laboratories, Johnson & Johnson, and Dexcom Inc. are heavily investing in R&D to innovate and expand their product lines. The competitive landscape is characterized by strategic partnerships and collaborations aimed at enhancing product offerings. The presence of advanced healthcare infrastructure and a high rate of diabetes awareness contribute to the region's market strength.

### Europe : Emerging Market with Regulations

Europe is the second-largest market for Point Of Care Glucose Testing Market, accounting for around 30% of the global market share. The region's growth is driven by increasing diabetes cases, an aging population, and a shift towards decentralized healthcare. Regulatory frameworks, such as the EU Medical Device Regulation, are enhancing product safety and efficacy, thereby boosting consumer confidence and market demand. The emphasis on preventive healthcare is also a significant driver of growth in this sector. Germany, France, and the UK are the leading countries in this market, with Germany holding the largest share. Key players like Roche Diagnostics and Siemens Healthineers are focusing on innovation and expanding their product portfolios. The competitive landscape is marked by collaborations between manufacturers and healthcare providers to improve patient outcomes. The presence of a robust healthcare system and increasing investments in health technology further support market expansion.

### Asia-Pacific : Rapidly Growing Market

Asia-Pacific is witnessing rapid growth in the Point Of Care Glucose Testing Market, holding approximately 20% of the global share. The region's growth is fueled by rising diabetes prevalence, increasing healthcare expenditure, and a growing focus on preventive healthcare. Countries like India and China are experiencing significant demand for glucose testing devices due to their large diabetic populations. Government initiatives aimed at improving healthcare access are also contributing to market expansion. China and India are the leading countries in this region, with a growing number of local and international players entering the market. Companies like Terumo Corporation and Nova Biomedical are expanding their presence through strategic partnerships and localized manufacturing. The competitive landscape is evolving, with an increasing emphasis on affordability and accessibility of testing solutions to cater to the diverse population needs.

### Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region represents an emerging market for Point Of Care Glucose Testing Market, holding about 5% of the global share. The growth is driven by increasing diabetes prevalence, rising healthcare investments, and a growing awareness of diabetes management. However, challenges such as limited healthcare infrastructure and regulatory hurdles can impede market growth. Governments are increasingly recognizing the importance of diabetes care, leading to initiatives aimed at improving healthcare access and quality. South Africa and the UAE are the leading markets in this region, with a growing number of international players entering the landscape. Companies are focusing on establishing partnerships with local healthcare providers to enhance distribution and accessibility. The competitive environment is characterized by a mix of global and regional players, with an emphasis on affordable testing solutions to meet the needs of diverse populations.

## Competitive Benchmarking

The Point Of Care Glucose Testing Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of diabetes globally. Key players such as Roche Diagnostics (Switzerland), Abbott Laboratories (US), and Dexcom Inc. (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Roche Diagnostics (Switzerland) focuses on innovation, particularly in developing integrated systems that combine glucose monitoring with data management solutions. Abbott Laboratories (US) emphasizes regional expansion, particularly in emerging markets, to capture a broader customer base. Meanwhile, Dexcom Inc. (US) is heavily investing in digital transformation, leveraging data analytics to improve patient outcomes and streamline operations. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and patient-centric solutions. In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that significantly influence trends and pricing. This competitive structure allows for a diverse range of products and services, catering to various consumer needs while fostering innovation through competition.
In August Abbott Laboratories (US) announced the launch of its latest continuous glucose monitoring system, which integrates seamlessly with mobile health applications. This strategic move not only enhances user experience but also positions Abbott as a leader in digital health solutions, potentially increasing its market share in the rapidly evolving landscape of diabetes management. The integration of mobile technology into glucose monitoring is likely to attract tech-savvy consumers, thereby expanding Abbott's customer base.
In September Roche Diagnostics (Switzerland) unveiled a new partnership with a leading telehealth provider to offer remote glucose monitoring services. This collaboration is strategically significant as it aligns with the growing trend of telemedicine, allowing Roche to tap into a broader market segment that prioritizes convenience and accessibility. By integrating their testing solutions with telehealth services, Roche is likely to enhance patient engagement and adherence to treatment protocols.
In October Dexcom Inc. (US) revealed advancements in its artificial intelligence algorithms designed to predict glucose fluctuations more accurately. This development is crucial as it not only improves the reliability of glucose monitoring but also positions Dexcom at the cutting edge of technology in diabetes management. The ability to provide predictive insights could significantly enhance patient outcomes, thereby solidifying Dexcom's competitive advantage in the market.
As of October current trends in the Point Of Care Glucose Testing Market indicate a strong shift towards digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage complementary strengths and enhance their product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of developing robust, patient-centric solutions that not only meet regulatory standards but also address the evolving needs of consumers.

## Recent News & Developments

- **Q2 2024: Abbott launches next-generation FreeStyle Libre 4 continuous glucose monitor in Europe** Abbott announced the commercial launch of its FreeStyle Libre 4, a next-generation continuous glucose monitoring system, in select European markets. The device features enhanced accuracy and new connectivity features for point-of-care and home use.
- **Q2 2024: Dexcom Receives FDA Clearance for G7 Continuous Glucose Monitoring System for Hospital Point-of-Care Use** Dexcom announced that the U.S. FDA has cleared its G7 continuous glucose monitoring system for use in hospital point-of-care settings, expanding its application beyond personal diabetes management.
- **Q1 2024: Roche launches Accu-Chek Instant Connect, a Bluetooth-enabled point-of-care glucose meter** Roche introduced the Accu-Chek Instant Connect, a new Bluetooth-enabled glucose meter designed for rapid point-of-care testing and seamless integration with electronic health records in clinical settings.
- **Q2 2024: Ascensia Diabetes Care and Glooko Announce Partnership to Integrate Point-of-Care Glucose Data with Digital Diabetes Management Platform** Ascensia Diabetes Care entered a partnership with Glooko to integrate data from its point-of-care glucose meters into Glooko’s digital diabetes management platform, enabling real-time data sharing between patients and healthcare providers.
- **Q3 2024: Trividia Health Receives CE Mark for TRUE METRIX AIR Professional Point-of-Care Glucose Meter** Trividia Health announced it has received CE Mark approval for its TRUE METRIX AIR Professional, a new point-of-care glucose meter intended for use in hospitals and clinics across Europe.
- **Q1 2024: PTS Diagnostics Launches New Point-of-Care Glucose and HbA1c Analyzer in the U.S.** PTS Diagnostics launched a new combined glucose and HbA1c analyzer for point-of-care use in the United States, targeting primary care clinics and community health centers.
- **Q2 2024: BioIntelliSense raises $45M Series B to expand wearable point-of-care glucose monitoring platform** BioIntelliSense secured $45 million in Series B funding to accelerate the development and commercialization of its wearable point-of-care glucose monitoring platform for both hospital and home settings.
- **Q2 2024: Siemens Healthineers acquires GlySure, expanding point-of-care glucose monitoring portfolio** Siemens Healthineers completed the acquisition of GlySure, a company specializing in continuous intravascular glucose monitoring, to strengthen its point-of-care diagnostics offerings.
- **Q3 2024: Nova Biomedical Opens New Manufacturing Facility for StatStrip Glucose Hospital Meters** Nova Biomedical opened a new manufacturing facility dedicated to producing its StatStrip point-of-care glucose meters for hospital use, aiming to meet growing demand in North America and Europe.
- **Q2 2025: AgaMatrix Receives FDA 510(k) Clearance for WaveSense Jazz Wireless Pro Point-of-Care Glucose Meter** AgaMatrix announced it has received FDA 510(k) clearance for its WaveSense Jazz Wireless Pro, a new point-of-care glucose meter designed for professional healthcare settings.
- **Q1 2025: EKF Diagnostics Launches STAT-Site WB Pro, a New Point-of-Care Glucose and Ketone Analyzer** EKF Diagnostics launched the STAT-Site WB Pro, a new analyzer capable of measuring both glucose and ketone levels at the point of care, targeting emergency and critical care environments.
- **Q2 2025: Medtronic Announces Partnership with Microsoft to Develop AI-Driven Point-of-Care Glucose Monitoring Solutions** Medtronic entered a partnership with Microsoft to co-develop artificial intelligence-powered solutions for point-of-care glucose monitoring, aiming to enhance clinical decision support and patient outcomes.

## Report Scope

| MARKET SIZE 2024 | 3.531(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 3.712(USD Billion) |
| MARKET SIZE 2035 | 6.105(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.1% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Bayer AG (DE), Johnson & Johnson (US), Siemens Healthineers (DE), Dexcom Inc. (US), Ascensia Diabetes Care (DE), Terumo Corporation (JP), Nova Biomedical (US) |
| Segments Covered | Product Type, Applications, End Users, Region |
| Key Market Opportunities | Integration of advanced digital health technologies enhances patient engagement in the Point Of Care Glucose Testing Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Point Of Care Glucose Testing Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Point Of Care Glucose Testing Market?**
A: The market valuation was 3.531 USD Billion in 2024.

**Q: What is the projected market size for the Point Of Care Glucose Testing Market by 2035?**
A: The market is projected to reach 6.105 USD Billion by 2035.

**Q: What is the expected CAGR for the Point Of Care Glucose Testing Market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.1% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the Point Of Care Glucose Testing Market?**
A: Key players include Roche Diagnostics, Abbott Laboratories, Bayer AG, Johnson & Johnson, Siemens Healthineers, Dexcom Inc., Ascensia Diabetes Care, Terumo Corporation, and Nova Biomedical.

**Q: What are the main segments of the Point Of Care Glucose Testing Market?**
A: The main segments include Type, Application, and End User.

**Q: How did the Blood-Glucose Meter segment perform in 2024?**
A: The Blood-Glucose Meter segment was valued at 2.468 USD Billion in 2024.

**Q: What is the projected value of the Lancing Devices and Strips segment by 2035?**
A: The Lancing Devices and Strips segment is projected to reach 1.823 USD Billion by 2035.

**Q: What is the market size for Type-1 Diabetes applications in 2024?**
A: The market size for Type-1 Diabetes applications was 1.063 USD Billion in 2024.

**Q: What is the expected market size for Home Care Settings by 2035?**
A: The market size for Home Care Settings is expected to reach 2.5 USD Billion by 2035.

**Q: How does the performance of the Others segment compare to other end users in 2024?**
A: The Others segment was valued at 0.531 USD Billion in 2024, indicating a smaller share compared to Hospitals and Clinics and Home Care Settings.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/point-of-care-glucose-testing-market-12264*